Aruna Subramanian

Clinical Professor, Medicine - Infectious Diseases

Bio

Clinical Focus: Chief, Immunocompromised Host Infectious Diseases

This includes the prevention, diagnosis and treatment of Infections in patients who are immunosuppressed because of:

Solid Organ Transplantation (Kidney, Pancreas, Liver, Heart, Lung, Small Bowel)
Bone Marrow (Hematopoeitic Cell) Transplants
Hematologic Malignancies
Chemotherapy for Solid Tumors
HIV who receive Chemotherapy,Solid Organ or Bone Marrow Transplants
Immunomodulators for Auto-Immune Diseases

Clinical Focus

Infectious Disease

Academic Appointments

Clinical Professor, Medicine - Infectious Diseases

Administrative Appointments

Co-PI, AIDS Clinical Trials Unit, Johns Hopkins University School of Medicine (2001 - 2003)
Co-Director, Transplant and Oncology ID Service, Johns Hopkins University School of Medicine (2003 - 2011)
Chief, Immunocompromised Host ID Service, Stanford University, Division of Infectious Diseases (2013 - Present)

Honors & Awards

Fellow of AST (FAST), American Society of Transplantation (2018)
Fellow of IDSA (FIDSA), Infectious Diseases Society of America (2014)
Sidney Finegold Outstanding Reviewer Award, Clinical Infectious Diseases Journal (2009)
Associate Editor, Transplant Infectious Diseases Journal (2004-2016)
Award for Outstanding Research, Case Western Reserve University (UHC) (1997)
William Dodd Robinson Award for Excellence in Internal Medicine, University of Michigan (1994)

Professional Education

Board Certification: American Board of Internal Medicine, Infectious Disease (1999)
Fellowship: Johns Hopkins University Division of Infectious Diseases (2000) MD
Medical Education: University of Michigan Medical School (1994) MI
Residency: University Hospitals of Cleveland - Case Western Reserve (1997) OH
Board Certification: American Board of Internal Medicine, Internal Medicine (1997)
Fellowship, Johns Hopkins University School of Medicine, Infectious Diseases (2001)
Residency, University Hospitals of Cleveland (Case Western Reserve), Internal Medicine (1997)
Medical School, University of Michigan, Medicine (1994)

Contact

Academic Tel: (650) 497-3492

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Infectious Disease Clinic 211 Quarry Rd Ste 202 MC 5988 Palo Alto CA 94304 Tel: (650) 736-5200 Fax: (650) 725-6908

Additional Clinical Info

Stanford Health Care

Current Research and Scholarly Interests

My research and scholarly interests have focused on tailoring antimicrobial prophylaxis in specific highly immunocompromised hosts depending on their specific infectious disease risks. I am interested in developing diagnostic algorithms and treatment protocols that will improve the quality of care in transplant and oncology patients.

I also have an interest in training ID fellows in this very specialized area of patient care. To that end, we have started a new ICHS ID fellowship with a specialized curriculum and are developing supplemental educational materials to enhance this training, which can be implemented at other academic training centers.

Clinical Trials

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Recruiting
More
The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.
Lead Sponsor
Stanford Investigators
- Aruna Subramanian
View full details
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) Recruiting
More
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
Lead Sponsor
Stanford Investigators
- Aruna Subramanian
View full details
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Recruiting
More
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Not Recruiting
More
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV upper respiratory tract infection (URTI), the effect of presatovir on development of lower respiratory tract complication, being free of any supplemental oxygen progression to respiratory failure, and pharmacokinetics (PK), safety, and tolerability of presatovir.

Stanford is currently not accepting patients for this trial. For more information, please contact Debbie Slamowitz , 650-723-2804.
Lead Sponsor
Stanford Investigators
View full details
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure Not Recruiting
More
The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect to overall survival (OS) of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) up to at least Study Day 91, with follow-up Protocol VTI-208E providing additional survival data up to a maximum of 5 years that will be included, as available, through VTI-208 study termination (after the last surviving enrolled subject completes Study Day 91). Secondary objectives are to determine the proportion of survivors at Study Days 28 and 91. Exploratory objectives are to evaluate the ability of ELAD to stabilize liver function, measured using the Model for End Stage Liver Disease (MELD)-based time to progression (TTP) up to Study Day 91, and the proportion of progression-free survivors (PFS) up to Study Days 28 and 91. Progression is defined as death or the first observed increase of at least 5 points from End of Study Day 1 MELD score (for both the ELAD and Control groups) until at least 24 hours after the ELAD Treatment Period is ended (end of Day 7 for Controls) and up to both End of Study Days 28 and 91 following Randomization.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
- Aruna Subramanian
- Timothy Angelotti MD, PhD
View full details
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Not Recruiting
More
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI).

Stanford is currently not accepting patients for this trial. For more information, please contact Debbie Slamowitz, 650-723-2804.
Lead Sponsor
Stanford Investigators
- Aruna Subramanian
- Dora Ho
View full details

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

Aruna Subramanian

Clinical Professor, Medicine - Infectious Diseases

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators